Peter Hillmen

Peter Hillmen

UNVERIFIED PROFILE

Are you Peter Hillmen?   Register this Author

Register author
Peter Hillmen

Peter Hillmen

Publications by authors named "Peter Hillmen"

Are you Peter Hillmen?   Register this Author

100Publications

4080Reads

7Profile Views

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Future Oncol 2020 Apr 24;16(10):517-523. Epub 2020 Mar 24.

Peter MacCallum Cancer Centre, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria 3000, Australia and University of Melbourne, Parkville, Victoria 3052, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0844DOI Listing
April 2020

Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPI-deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry.

Br J Haematol 2020 Feb 27. Epub 2020 Feb 27.

Section of Experimental Haematology and Immunology, Leeds Institute of Medical Research at St. James's, School of Medicine, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16427DOI Listing
February 2020

Telomere length predicts for outcome to FCR chemotherapy in CLL.

Leukemia 2019 08 30;33(8):1953-1963. Epub 2019 Jan 30.

Division of Cancer & Genetics, Cardiff University, School of Medicine, Heath Park, Cardiff, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-019-0389-9
Publisher Site
http://dx.doi.org/10.1038/s41375-019-0389-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756045PMC
August 2019

Trial re-investment to build better research for better impact.

Lancet 2019 Aug;394(10199):635-636

Department of Haematology, St James's University Hospital, Leeds, LS9 7TF, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)31363-7DOI Listing
August 2019

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells.

Oncogenesis 2019 May 10;8(5):32. Epub 2019 May 10.

Section of Experimental Haematology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41389-019-0142-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510766PMC
May 2019

Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.

Leuk Lymphoma 2019 Apr 2;60(4):1000-1005. Epub 2018 Oct 2.

f Department of Medicine , University of California San Diego, Moores Cancer Center , San Diego , CA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1512710DOI Listing
April 2019

Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia.

Br J Haematol 2018 09 2;182(6):927-930. Epub 2017 Aug 2.

Department of Haematology, St. James's University Hospital, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14884DOI Listing
September 2018

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

J Clin Oncol 2018 07 1;36(19):1973-1980. Epub 2018 May 1.

Stephan Stilgenbauer and Johannes Bloehdorn, Ulm University, Ulm; Stephan Stilgenbauer, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; Barbara Eichhorst and Michael Hallek, Universitätsklinikum Köln, Köln; Johannes Schetelig, University Hospital, Technische Universität Dresden, Dresden; Clemens-Martin Wendtner, Klinikum Schwabing, Munich; Sebastian Böttcher, University Hospital of Schleswig-Holstein, Kiel, Germany; Peter Hillmen and Talha Munir, St James's University Hospital, Leeds; Anna Schuh, University of Oxford; Anna Schuh, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; John F. Seymour, Peter MacCallum Cancer Centre; John F. Seymour, University of Melbourne; Andrew W. Roberts, Royal Melbourne Hospital, Parkville, Victoria; Stephen P. Mulligan, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Steven Coutre, Stanford University Medical Center, Stanford, CA; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Sarit Assouline, McGill University, Montreal, Quebec, Canada; Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, and Gary Gordon, AbbVie, North Chicago, IL; Ahmed Hamed Salem, Ain Shams University, Cairo, Egypt; and William G. Wierda, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6840DOI Listing
July 2018

An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.

BMC Res Notes 2018 May 8;11(1):280. Epub 2018 May 8.

Leicester Cancer Research Centre and Ernest and Helen Scott Haematological Research Unit, University of Leicester, Room 104, Hodgkin Building, Lancaster Road, Leicester, LE1 7HB, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13104-018-3391-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941460PMC
May 2018

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

N Engl J Med 2018 Mar;378(12):1107-1120

From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) - all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) - both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne-Bonn, Cologne, Germany (B.E.); St. James's University Hospital, Leeds (P.H.), and F. Hoffmann-La Roche, Welwyn Garden City (M.B., K.H.) - both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) - all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713976DOI Listing
March 2018

Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia.

BMJ Case Rep 2017 Nov 8;2017. Epub 2017 Nov 8.

NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2017-221065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695391PMC
November 2017

Minimal residual disease is an independent predictor for 10-year survival in CLL.

Blood 2016 12 3;128(24):2770-2773. Epub 2016 Oct 3.

Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-05-714162DOI Listing
December 2016

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

Blood 2016 Feb 12;127(5):582-95. Epub 2015 Nov 12.

School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-05-644872DOI Listing
February 2016

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 7;374(4):323-32. Epub 2015 Dec 7.

From the Division of Hematology, Department of Internal Medicine, Ohio State University (J.C. Byrd, J.A.J., F.T.A., J.W., A.J.J.), and the Department of Veterinary Biosciences, College of Veterinary Medicine (B.H.) - both in Columbus; UC Irvine Health Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange (S.O.); University of Oxford, Oxford (A.S.), NHS Foundation Trust, King's College Hospital, London (S.D.), and the Department of Haematology, St. James's University Hospital, Leeds (P.H.) - all in the United Kingdom; Northwest Medical Specialties, Tacoma (J.C.), and the Swedish Cancer Institute, Seattle (J.M.P.) - both in Washington; the Department of Leukemia, Division of Cancer Medicine, University of Texas, and M.D. Anderson Cancer Center - both in Houston (W.G.W.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (D.M.S.); Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milan (P.G.); Hofstra North Shore-LIJ School of Medicine, Chronic Lymphocytic Leukemia Research and Treatment Center, Lake Success (J.C. Barrientos), and the Department of Pathology and Cell Biology, Columbia University Medical Center (T.G.D.), and New York-Presbyterian/Weill Cornell Medical Center, New York (R.R.F.) - all in New York; and Acerta Pharma, Oss, the Netherlands (D.J., J.H., X.W., A.K., B.J.L., T.C., M.F., J.M., A.H., W.R., R.I.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862586PMC
January 2016

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

N Engl J Med 2015 Dec 6;373(25):2425-37. Epub 2015 Dec 6.

From the University of Texas MD Anderson Cancer Center, Houston (J.A.B.); Azienda Ospedaliera Niguarda Cà Granda (A.T.) and Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele (P.G.), Milan, and the Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara (G.G.) - all in Italy; Wilmot Cancer Institute, University of Rochester, Rochester, NY (P.M.B.); Medical University of Lodz and Copernicus Memorial Hospital, Lodz (T.R.), the Department of Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice (S.G.), and the Department of Hematology, University Clinical Center of Medical University of Gdansk, Gdansk (A.H.) - all in Poland; Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv (O.B.), and Hadassah University Hospital, Hebrew University Medical School, Jerusalem (A.P.) - both in Israel; Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds (P.H.), Kings College Hospital, London (S.D.), Royal Bournemouth Hospital, Bournemouth (H.M.), and University of Oxford, Oxford (A.S.) - all in the United Kingdom; Washington University School of Medicine, St. Louis (N.L.B.); Jiangsu Province Hospital, Nanjing, China (J.L.); North Shore Hospital, Auckland, New Zealand (D. Simpson); Stanford University School of Medicine, Stanford (S.C.), City of Hope National Medical Center, Duarte (T.S.), Pharmacyclics, Sunnyvale (D. Suri, M.C., F.C., L.S., D.F.J.), and Moores Cancer Center, University of California, San Diego, San Diego (T.J.K.) - all in California; St. Vincent's Hospital, University of Melbourne (H.Q.), and Peter MacCallum Cancer Centre and St. Vincent's Hospital (C.S.T.), Melbourne, VIC, Australia; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine (Z.M.); Norton Cancer Institute, Louisville, KY (D.A.S.);

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722809PMC
December 2015

Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: a deficiency of NK cells, but not an NK cell deficiency.

Blood 2015 Feb;125(8):1351-2

Leeds Institute of Cancer and Pathology, University of Leeds School of Medicine, Leeds, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-07-591255DOI Listing
February 2015

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

J Clin Oncol 2014 Apr 17;32(12):1236-41. Epub 2014 Mar 17.

Peter Hillmen, Abraham Varghese, and Andy Rawstron, St James's Institute of Oncology; Dena Cohen, University of Leeds, Leeds; John G. Gribben, Barts and the London School of Medicine; Claire E. Dearden, Royal Marsden Hospital; Amit Nathwani, University College London, London; George A. Follows, Addenbrooke's Hospital, Cambridge; Donald Milligan, Heartlands Hospital, Birmingham; Hazem A. Sayala, Hull and East Yorkshire Hospitals, Hull; Paul Moreton, Pinderfields General Hospital, Wakefield; David G. Oscier, Royal Bournemouth Hospital, Bournemouth; Daniel B. Kennedy, Leicester Royal Infirmary, Leicester; Andrew R. Pettitt, Royal Liverpool and Broadgreen University Hospitals National Health Service Trust, Liverpool; Christopher F.E. Pocock, East Kent Hospitals, Canterbury, United Kingdom; and Stephan Oertel, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.6547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876343PMC
April 2014

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

N Engl J Med 2014 Mar 22;370(11):997-1007. Epub 2014 Jan 22.

Weill Cornell Medical College (R.R.F.), Memorial Sloan-Kettering Cancer Center (A.D.Z.), the Department of Medicine, and Columbia University Medical Center (N.L.) - all in New York; U.S. Oncology Research, Springfield, OR (J.P.S.); Stanford University School of Medicine, Stanford (S.E.C.), and Gilead Sciences, Foster City (M.A., D.M.J., L.L.M., D.L., T.M.J., R.D.D.) - both in California; Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC (B.D.C.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (J.M.P.); St. James's University Hospital, Leeds (P.H.), and Royal Liverpool University Hospital, Liverpool (A.R.P.) - both in the United Kingdom; Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York (J.C.B.); University of California San Diego, Moores Cancer Center, La Jolla (T.J.K.); Sarah Cannon Research Institute, Nashville (I.F.); Universita Vita-Salute San Raffaele, Instituto Scientifico San Raffaele, Milan (P.G.); David Geffen School of Medicine, University of California Los Angeles, Los Angeles (H.E.); Florida Cancer Specialists, Englewood (T.E.); Centre Hospitalier Lyon-Sud, Pierre-Bénite, France (B.C.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (S.M.); University of Ulm, Ulm (S.S.), and University of Cologne, Cologne (P.C., M.H.) - both in Germany; and University of Texas M.D. Anderson Cancer Center, Houston (S.M.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1315226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365PMC
March 2014

Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab.

Int J Hematol 2013 Dec 25;98(6):716-8. Epub 2013 Oct 25.

Department of Hematology/Oncology, St-James University Hospital, Beckett Street, Leeds, LS9 7TF, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-013-1454-1DOI Listing
December 2013

Thrombosis in paroxysmal nocturnal hemoglobinuria.

Blood 2013 Jun 22;121(25):4985-96; quiz 5105. Epub 2013 Apr 22.

Department of Haematology, St. James's University Hospital, Leeds, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-09-311381DOI Listing
June 2013

Richter's syndrome: CLL taking a turn for the worse.

Authors:
Peter Hillmen

Oncology (Williston Park) 2012 Dec;26(12):1155-6

St James's University Hospital, Leeds, UK.

View Article

Download full-text PDF

Source
December 2012

Update in paroxysmal nocturnal hemoglobinuria.

Authors:
Peter Hillmen

Clin Adv Hematol Oncol 2012 Jun;10(6):391-3

Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

View Article

Download full-text PDF

Source
June 2012